カテゴリー： 世界, 医療/バイオ, Mordor Intelligence

世界のヒトインスリン薬剤市場2023年-2028年：成長・動向・新型コロナの影響・市場予測

【英語タイトル】Human Insulin Drugs Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Mordor Intelligenceが出版した調査資料（MOR23MAC015）・商品コード：MOR23MAC015
・発行会社（調査会社）：Mordor Intelligence
・発行日：2023年1月23日
・ページ数：176
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：アメリカ、カナダ、フランス、ドイツ、イタリア、スペイン、イギリス、ロシア、メキシコ、ブラジル、日本、韓国、中国、インド、オーストラリア、ベトナム、マレーシア、インドネシア、フィリピン、タイ、サウジアラビア、イラン、エジプト、オマーン、南アフリカ
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,750 ⇒換算￥722,000見積依頼/購入/質問フォーム
Corporate License（複数拠点内で共有可）USD8,750 ⇒換算￥1,330,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Mordor Intelligence社は、世界のヒトインスリン薬剤市場規模が、予測期間中、年平均3％で成長し、2027年には320億ドルへ達すると見込んでいます。当書では、ヒトインスリン薬剤の世界市場を対象に、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品種類別（基礎/長時間作用型インスリン、ノボラピッド/ノボログ（インスリンアスパルト）、従来型ヒトインスリン、混合型インスリン、バイオシミラーインスリン）分析、地域別（アメリカ、カナダ、フランス、ドイツ、イタリア、スペイン、イギリス、ロシア、メキシコ、ブラジル、日本、韓国、中国、インド、オーストラリア、ベトナム、マレーシア）分析、競争状況、市場機会・将来動向などについて調査・分析を行い、調査レポートにまとめています。なお、こちらに記載のある企業情報には、Novo Nordisk A/S、Sanofi S.A.、Eli Lilly and Company、Biocon Limited、Pfizer Inc.、Wockhardt、Julphar、Exir、Sedicoなどが含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界のヒトインスリン薬剤市場規模：製品種類別
- 基礎/長時間作用型インスリンの市場規模
- ノボラピッド/ノボログ（インスリンアスパルト）の市場規模
- 従来型ヒトインスリンの市場規模
- 混合型インスリンの市場規模
- バイオシミラーインスリンの市場規模
・世界のヒトインスリン薬剤市場規模：地域別
- 北米のヒトインスリン薬剤市場規模
アメリカのヒトインスリン薬剤市場規模
カナダのヒトインスリン薬剤市場規模
- ヨーロッパのヒトインスリン薬剤市場規模
フランスのヒトインスリン薬剤市場規模
ドイツのヒトインスリン薬剤市場規模
イタリアのヒトインスリン薬剤市場規模
…
- アジア太平洋のヒトインスリン薬剤市場規模
日本のヒトインスリン薬剤市場規模
韓国のヒトインスリン薬剤市場規模
中国のヒトインスリン薬剤市場規模
…
- 南米/中東のヒトインスリン薬剤市場規模
メキシコのヒトインスリン薬剤市場規模
ブラジルのヒトインスリン薬剤市場規模
…
・競争状況
・市場機会・将来動向

Human Insulin Drugs Market is likely to reach USD 32 billion by 2027 at a CAGR greater than 3% over the forecast period.

The COVID-19 pandemic has had a substantial impact on the Human Insulin Drugs Market. Type-1 diabetes patients are impacted more during Covid-19. People with diabetes are having a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes will have more chances to get into serious complications rather than normal people.

Diabetes is associated with many health complications. People with diabetes have a 300% increased risk of being hospitalized compared to those without diabetes, and thus, they incur more healthcare expenses compared to non-diabetic people. Patients with Type 2 diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates. Furthermore, patients attempting to control their blood glucose levels, so as to prevent the long-term complications associated with fluctuations in blood glucose levels, are at greater risk for overcorrection and the resultant hypoglycemia.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Human Insulin Drugs Market Trends

Growing Diabetes Prevalence Driving the Market

All Type 1 diabetes patients and a limited number of Type 2 diabetes patients require daily insulin injections as part of their treatment. As per the ADA, around 67.3% of the cost of diabetes care in the United States is provided by government insurance (including Medicare, Medicaid, and the military). The rest is paid for by private insurance (30.7%) or by the uninsured (2%).

In Canada, the total diabetic population in the country increased by approximately 32% between 2016-2020, and about 8% of the diabetic population has Type 1 diabetes. Many developing countries in North America, including the Caribbean countries, are undergoing an epidemiologic transition and experiencing rapid increases in the prevalence of diabetes.

As of 2021, the prevalence rates for diabetes ranged from 12% to 19% of the population in several countries in the region.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the Market.

North America Dominates the Market

North America dominates the global human insulin market, especially the United States, owing to the high prevalence of diabetes in the region because of a sedentary lifestyle. The cost factor is the major concern in the United States, where almost 50% of the insulin revenues for the manufacturers are from the country itself. The United States accounts for the highest sales of long-acting insulin, Lantus, across the world. Most diabetic drug manufacturing companies consider the country as a critical market for improving overall global sales. Lantus is the most administered basal insulin across the world, accounting for a dominant share in the US market. The traditional North American human insulin drugs market is expected to grow during the forecast period, due to its economic affordability to patients. Humulin holds the highest market share, followed by Novolin. There are no generic competitors for the traditional North American human insulin drugs market in the United States.

The United States accounts for the highest sales of Humalog across the world, with over 56% of the market share. The majority of the diabetes drug manufacturing companies consider the country a critical market for improving overall global sales. In the United States, Humalog is available in different varieties under names like Humalog Mix 75/25, Humalog U-100, Humalog U-200, and Humalog Mix 50/50 for the treatment of diabetes.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the Human Insulin Drugs Market.

Human Insulin Drugs Market Competitor Analysis

The global human insulin market is highly consolidated with three major manufacturers holding a global market presence, and the remaining manufacturers confined to the other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (Insulin Glargine). Biocon is developing Insulin Tregopil, an oral prandial insulin tablet, for the treatment of type-1 and type-2 diabetes mellitus. The fast-acting oral insulin could improve post-prandial glucose control with reduced side effects and greater adherence, thus holding the promise to transform T1D management. Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, focused on the development of oral drug delivery systems, is working to bring the first oral insulin product to market, thus, providing a more convenient, effective, as well as a safer method for delivering insulin therapy.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Basal or Long-acting Insulins (Value and Volume, 2016 – 2027)
5.1.1.1 Lantus (Insulin glargine)
5.1.1.2 Levemir (Insulin detemir)
5.1.1.3 Toujeo (Insulin glargine)
5.1.1.4 Tresiba (Insulin degludec)
5.1.1.5 Basaglar (Insulin glargine)
5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2016 – 2027)
5.1.2.1 NovoRapid/Novolog (Insulin aspart)
5.1.2.2 Humalog (Insulin lispro)
5.1.2.3 Apidra (Insulin glulisine)
5.1.2.4 FIASP (Insulin aspart)
5.1.2.5 Admelog (Insulin lispro)
5.1.3 Traditional Human Insulins (Value and Volume, 2016 – 2027)
5.1.3.1 Novolin/Actrapid/Insulatard
5.1.3.2 Humulin
5.1.3.3 Insuman
5.1.4 Combination Insulins (Value and Volume, 2016 – 2027)
5.1.4.1 NovoMix (Biphasic Insulin aspart)
5.1.4.2 Ryzodeg (Insulin degludec/Insulin aspart)
5.1.4.3 Xultophy (Insulin degludec/Liraglutide)
5.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)
5.1.5 Biosimilar Insulins (Value and Volume, 2016 – 2027)
5.1.5.1 Insulin Glargine Biosimilars
5.1.5.2 Human Insulin Biosimilars
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume, 2016 – 2027)
5.2.1.1.1 Basal or Long-acting Insulins
5.2.1.1.2 Bolus or Fast-acting Insulins
5.2.1.1.3 Traditional Human Insulins
5.2.1.1.4 Combination Insulins
5.2.1.1.5 Biosimilar Insulins
5.2.1.2 Canada (Value and Volume, 2016 – 2027)
5.2.1.2.1 Basal or Long-acting Insulins
5.2.1.2.2 Bolus or Fast-acting Insulins
5.2.1.2.3 Traditional Human Insulins
5.2.1.2.4 Combination Insulins
5.2.1.2.5 Biosimilar Insulins
5.2.1.3 Rest of North America (Value and Volume, 2016 – 2027)
5.2.1.3.1 Basal or Long-acting Insulins
5.2.1.3.2 Bolus or Fast-acting Insulins
5.2.1.3.3 Traditional Human Insulins
5.2.1.3.4 Combination Insulins
5.2.1.3.5 Biosimilar Insulins
5.2.2 Europe
5.2.2.1 France (Value and Volume, 2016 – 2027)
5.2.2.1.1 Basal or Long-acting Insulins
5.2.2.1.2 Bolus or Fast-acting Insulins
5.2.2.1.3 Traditional Human Insulins
5.2.2.1.4 Combination Insulins
5.2.2.1.5 Biosimilar Insulins
5.2.2.2 Germany (Value and Volume, 2016 – 2027)
5.2.2.2.1 Basal or Long-acting Insulins
5.2.2.2.2 Bolus or Fast-acting Insulins
5.2.2.2.3 Traditional Human Insulins
5.2.2.2.4 Combination Insulins
5.2.2.2.5 Biosimilar Insulins
5.2.2.3 Italy (Value and Volume, 2016 – 2027)
5.2.2.3.1 Basal or Long-acting Insulins
5.2.2.3.2 Bolus or Fast-acting Insulins
5.2.2.3.3 Traditional Human Insulins
5.2.2.3.4 Combination Insulins
5.2.2.3.5 Biosimilar Insulins
5.2.2.4 Spain (Value and Volume, 2016 – 2027)
5.2.2.4.1 Basal or Long-acting Insulins
5.2.2.4.2 Bolus or Fast-acting Insulins
5.2.2.4.3 Traditional Human Insulins
5.2.2.4.4 Combination Insulins
5.2.2.4.5 Biosimilar Insulins
5.2.2.5 United Kingdom (Value and Volume, 2016 – 2027)
5.2.2.5.1 Basal or Long-acting Insulins
5.2.2.5.2 Bolus or Fast-acting Insulins
5.2.2.5.3 Traditional Human Insulins
5.2.2.5.4 Combination Insulins
5.2.2.5.5 Biosimilar Insulins
5.2.2.6 Russia (Value and Volume, 2016 – 2027)
5.2.2.6.1 Basal or Long-acting Insulins
5.2.2.6.2 Bolus or Fast-acting Insulins
5.2.2.6.3 Traditional Human Insulins
5.2.2.6.4 Combination Insulins
5.2.2.6.5 Biosimilar Insulins
5.2.2.7 Rest of Europe (Value and Volume, 2016 – 2027)
5.2.2.7.1 Basal or Long-acting Insulins
5.2.2.7.2 Bolus or Fast-acting Insulins
5.2.2.7.3 Traditional Human Insulins
5.2.2.7.4 Combination Insulins
5.2.2.7.5 Biosimilar Insulins
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume, 2016 – 2027)
5.2.3.1.1 Basal or Long-acting Insulins
5.2.3.1.2 Bolus or Fast-acting Insulins
5.2.3.1.3 Traditional Human Insulins
5.2.3.1.4 Combination Insulins
5.2.3.1.5 Biosimilar Insulins
5.2.3.2 Brazil (Value and Volume, 2016 – 2027)
5.2.3.2.1 Basal or Long-acting Insulins
5.2.3.2.2 Bolus or Fast-acting Insulins
5.2.3.2.3 Traditional Human Insulins
5.2.3.2.4 Combination Insulins
5.2.3.2.5 Biosimilar Insulins
5.2.3.3 Rest of Latin America (Value and Volume, 2016 – 2027)
5.2.3.3.1 Basal or Long-acting Insulins
5.2.3.3.2 Bolus or Fast-acting Insulins
5.2.3.3.3 Traditional Human Insulins
5.2.3.3.4 Combination Insulins
5.2.3.3.5 Biosimilar Insulins
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume, 2016 – 2027)
5.2.4.1.1 Basal or Long-acting Insulins
5.2.4.1.2 Bolus or Fast-acting Insulins
5.2.4.1.3 Traditional Human Insulins
5.2.4.1.4 Combination Insulins
5.2.4.1.5 Biosimilar Insulins
5.2.4.2 South Korea (Value and Volume, 2016 – 2027)
5.2.4.2.1 Basal or Long-acting Insulins
5.2.4.2.2 Bolus or Fast-acting Insulins
5.2.4.2.3 Traditional Human Insulins
5.2.4.2.4 Combination Insulins
5.2.4.2.5 Biosimilar Insulins
5.2.4.3 China (Value and Volume, 2016 – 2027)
5.2.4.3.1 Basal or Long-acting Insulins
5.2.4.3.2 Bolus or Fast-acting Insulins
5.2.4.3.3 Traditional Human Insulins
5.2.4.3.4 Combination Insulins
5.2.4.3.5 Biosimilar Insulins
5.2.4.4 India (Value and Volume, 2016 – 2027)
5.2.4.4.1 Basal or Long-acting Insulins
5.2.4.4.2 Bolus or Fast-acting Insulins
5.2.4.4.3 Traditional Human Insulins
5.2.4.4.4 Combination Insulins
5.2.4.4.5 Biosimilar Insulins
5.2.4.5 Australia (Value and Volume, 2016 – 2027)
5.2.4.5.1 Basal or Long-acting Insulins
5.2.4.5.2 Bolus or Fast-acting Insulins
5.2.4.5.3 Traditional Human Insulins
5.2.4.5.4 Combination Insulins
5.2.4.5.5 Biosimilar Insulins
5.2.4.6 Vietnam (Value and Volume, 2016 – 2027)
5.2.4.6.1 Basal or Long-acting Insulins
5.2.4.6.2 Bolus or Fast-acting Insulins
5.2.4.6.3 Traditional Human Insulins
5.2.4.6.4 Combination Insulins
5.2.4.6.5 Biosimilar Insulins
5.2.4.7 Malaysia (Value and Volume, 2016 – 2027)
5.2.4.7.1 Basal or Long-acting Insulins
5.2.4.7.2 Bolus or Fast-acting Insulins
5.2.4.7.3 Traditional Human Insulins
5.2.4.7.4 Combination Insulins
5.2.4.7.5 Biosimilar Insulins
5.2.4.8 Indonesia (Value and Volume, 2016 – 2027)
5.2.4.8.1 Basal or Long-acting Insulins
5.2.4.8.2 Bolus or Fast-acting Insulins
5.2.4.8.3 Traditional Human Insulins
5.2.4.8.4 Combination Insulins
5.2.4.8.5 Biosimilar Insulins
5.2.4.9 Philippines (Value and Volume, 2016 – 2027)
5.2.4.9.1 Basal or Long-acting Insulins
5.2.4.9.2 Bolus or Fast-acting Insulins
5.2.4.9.3 Traditional Human Insulins
5.2.4.9.4 Combination Insulins
5.2.4.9.5 Biosimilar Insulins
5.2.4.10 Thailand (Value and Volume, 2016 – 2027)
5.2.4.10.1 Basal or Long-acting Insulins
5.2.4.10.2 Bolus or Fast-acting Insulins
5.2.4.10.3 Traditional Human Insulins
5.2.4.10.4 Combination Insulins
5.2.4.10.5 Biosimilar Insulins
5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2016 – 2027)
5.2.4.11.1 Basal or Long-acting Insulins
5.2.4.11.2 Bolus or Fast-acting Insulins
5.2.4.11.3 Traditional Human Insulins
5.2.4.11.4 Combination Insulins
5.2.4.11.5 Biosimilar Insulins
5.2.5 Middle-East
5.2.5.1 Saudi Arabia (Value and Volume, 2016 – 2027)
5.2.5.1.1 Basal or Long-acting Insulins
5.2.5.1.2 Bolus or Fast-acting Insulins
5.2.5.1.3 Traditional Human Insulins
5.2.5.1.4 Combination Insulins
5.2.5.1.5 Biosimilar Insulins
5.2.5.2 Iran (Value and Volume, 2016 – 2027)
5.2.5.2.1 Basal or Long-acting Insulins
5.2.5.2.2 Bolus or Fast-acting Insulins
5.2.5.2.3 Traditional Human Insulins
5.2.5.2.4 Combination Insulins
5.2.5.2.5 Biosimilar Insulins
5.2.5.3 Egypt (Value and Volume, 2016 – 2027)
5.2.5.3.1 Basal or Long-acting Insulins
5.2.5.3.2 Bolus or Fast-acting Insulins
5.2.5.3.3 Traditional Human Insulins
5.2.5.3.4 Combination Insulins
5.2.5.3.5 Biosimilar Insulins
5.2.5.4 Oman (Value and Volume, 2016 – 2027)
5.2.5.4.1 Basal or Long-acting Insulins
5.2.5.4.2 Bolus or Fast-acting Insulins
5.2.5.4.3 Traditional Human Insulins
5.2.5.4.4 Combination Insulins
5.2.5.4.5 Biosimilar Insulins
5.2.5.5 South Africa (Value and Volume, 2016 – 2027)
5.2.5.5.1 Basal or Long-acting Insulins
5.2.5.5.2 Bolus or Fast-acting Insulins
5.2.5.5.3 Traditional Human Insulins
5.2.5.5.4 Combination Insulins
5.2.5.5.5 Biosimilar Insulins
5.2.5.6 Rest of Middle-East (Value and Volume, 2016 – 2027)
5.2.5.6.1 Basal or Long-acting Insulins
5.2.5.6.2 Bolus or Fast-acting Insulins
5.2.5.6.3 Traditional Human Insulins
5.2.5.6.4 Combination Insulins
5.2.5.6.5 Biosimilar Insulins

6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2016 – 2027)
6.2 Type 2 Diabetes Population (2016 – 2027)

7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk A/S
7.1.1.1 Overview
7.1.1.2 Products and Strategies
7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.1.4 Ratio Analysis (5 Years)
7.1.1.5 Strength and Stability Analysis (5 Years)
7.1.1.6 Recent Developments
7.1.2 Sanofi S.A.
7.1.2.1 Overview
7.1.2.2 Products and Strategies
7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.2.4 Ratio Analysis (5 Years)
7.1.2.5 Strength and Stability Analysis (5 Years)
7.1.2.6 Recent Developments
7.1.3 Eli Lilly and Company
7.1.3.1 Overview
7.1.3.2 Products and Strategies
7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.3.4 Ratio Analysis (5 Years)
7.1.3.5 Strength and Stability Analysis (5 Years)
7.1.3.6 Recent Developments
7.1.4 Biocon Limited
7.1.4.1 Overview
7.1.4.2 Products and Strategies
7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.4.4 Ratio Analysis (5 Years)
7.1.4.5 Strength and Stability Analysis (5 Years)
7.1.4.6 Recent Developments
7.1.5 Pfizer Inc.
7.1.5.1 Overview
7.1.5.2 Products and Strategies
7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.5.4 Ratio Analysis (5 Years)
7.1.5.5 Strength and Stability Analysis (5 Years)
7.1.5.6 Recent Developments
7.1.6 Wockhardt
7.1.6.1 Overview
7.1.6.2 Products and Strategies
7.1.6.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)
7.1.6.4 Ratio Analysis (5 Years)
7.1.6.5 Strength and Stability Analysis (5 Years)
7.1.6.6 Recent Developments
7.1.7 Julphar
7.1.7.1 Overview
7.1.7.2 Products and Strategies
7.1.7.3 Recent Developments
7.1.8 Exir
7.1.8.1 Overview
7.1.8.2 Products and Strategies
7.1.8.3 Recent Developments
7.1.9 Sedico
7.1.9.1 Overview
7.1.9.2 Products and Strategies
7.1.9.3 Recent Developments
7.2 COMPANY SHARE ANALYSIS
7.2.1 Novo Nordisk AS
7.2.2 Sanofi Aventis
7.2.3 Eli Lilly
7.2.4 Other Companies

8 MARKET OPPORTUNITIES AND FUTURE TRENDS



★調査レポート[世界のヒトインスリン薬剤市場2023年-2028年：成長・動向・新型コロナの影響・市場予測] (コード：MOR23MAC015)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のヒトインスリン薬剤市場2023年-2028年：成長・動向・新型コロナの影響・市場予測]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の糖尿病治療薬市場2023年-2028年：成長・動向・新型コロナの影響・市場予測
  • 世界のインスリン注入ポンプ市場2023年-2028年：成長・動向・新型コロナの影響・市場予測
  • 世界のインスリンデリバリー機器市場2023年-2028年：成長・動向・新型コロナの影響・市場予測
  • 世界の持続血糖モニタリング（CGM）市場2023年-2028年：成長・動向・新型コロナの影響・市場予測
  • 世界のインスリングラルギン市場2023年-2028年：成長・動向・新型コロナの影響・市場予測
  • 世界のシリンジ市場2023年-2028年：成長・動向・新型コロナの影響・市場予測
  • 世界の避妊薬（ピル）市場2023年-2028年：成長・動向・新型コロナの影響・市場予測
  • 世界のメタノール市場2023年-2028年：成長・動向・新型コロナの影響・市場予測
  • 世界の感染症診断市場2023年-2028年：成長・動向・新型コロナの影響・市場予測

    • ◆H&Iグローバルリサーチのお客様（例）◆